Oil
GSK

Bayer, CureVac terminate COVID-19 shot production partnership

Credit: REUTERS/POOL

Bayer AG has terminated a vaccine manufacturing partnership under which it would have helped produce CureVac's COVID-19 shot, a spokesperson for Bayer told a German newspaper.

FRANKFURT, Oct 15 (Reuters) - Bayer AG BAYGn.DE has terminated a vaccine manufacturing partnership under which it would have helped produce CureVac's 5CV.DE COVID-19 shot, a spokesperson for Bayer told a German newspaper.

The news comes after CureVac earlier this week said it will give up on its first-generation COVID-19 vaccine candidate and instead focus on collaborating with GSK GSK.L to develop improved mRNA vaccine technology.

"Jointly with CureVac we have decided by mutual agreement to not continue the cooperation," the Bayer spokesperson told Rheinische Post.

Bayer in February said it expected to produce 160 million doses of the CureVac shot in 2022 at its Wuppertal site in western Germany.

(Reporting by Christoph Steitz Editing by Bill Berkrot)

((christoph.steitz@thomsonreuters.com; +49 30 220 133 647;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK CVAC

Latest Oil Videos

Biden Taps U.S. Oil Reserves in Coordinated Multi-Nation Release

Nov 23, 2021

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More